Stock listing

OTC:BOVNF BioInvent International AB Stock

US listing (OTC) of BioInvent International AB · home listing Stockholm:BINV

Follow BioInvent International AB into a list and get an email when it puts out news.

Share price · OTC:BOVNF

$0.28 USD 0.00 (0.0%)

Close on Nov 11, 2026

Past year -91.5% · daily closes, Nov 11, 2025 – Nov 11, 2026, adjusted for splits
Day range
$0.28 – $0.28 USDNov 11, 2026
52-week range
$0.28 – $3.29 USDLowest and highest trades, Nov 12, 2025 – Nov 11, 2026
Traded on an average day
$126 USDMedian day 0 shares · 61 days with no trades · last 3 months, Aug 11, 2026 – Nov 11, 2026
BioInvent International AB logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
Stockholm:BINV · Home2.75 SEK-0.165 (-5.7%)215,2092.912.9452.662.915Close on Nov 16, 2026
Frankfurt:BIX0€0.269 EUR+0.003 (+1.1%)—€0.257€0.269€0.257€0.266Close on Nov 13, 2026
OTC:BOVNF$0.28 USD0.00 (0.0%)—$0.28$0.28$0.28$0.28Close on Nov 11, 2026

Daily closes

Last 3 months, Aug 11, 2026 – Nov 11, 2026 · OTC:BOVNF · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.280.000.0%$0.28$0.28$0.280
$0.280.000.0%$0.28$0.28$0.280
$0.28-0.12-30.0%$0.28$0.28$0.28650
$0.400.000.0%$0.40$0.40$0.402,500
$0.400.000.0%$0.40$0.40$0.400
$0.400.000.0%$0.40$0.40$0.400
$0.40-0.045-10.0%$0.40$0.40$0.402,500
$0.444-0.166-27.2%$0.549$0.549$0.4447,000
$0.610.000.0%$0.61$0.61$0.610
$0.61-2.679-81.5%$0.753$0.93$0.615,000
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890
$3.2890.000.0%$3.289$3.289$3.2890

Splits

1 split · OTC:BOVNF · every price before a split is adjusted for it

DayRatioWhat
1-for-25Consolidation
Ticker
OTC:BOVNF
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
OTC
Currency
USD

What changed lately

Calls

Replays

  • BioInvent International (Stockholm:BINV) Q4 2025 Earnings Call

    Thu, Feb 26, 2026 · 8:00 AM ET

    Watch Transcript
  • BioInvent International (Stockholm:BINV) Q3 2025 Earnings Call

    Wed, Oct 29, 2025 · 9:00 AM ET

    Watch Transcript

Latest news

All BioInvent International AB news

Financings

  • Rights offering of new shares with preferential rights

    Oct 28, 2026 · US$43.28M

    Announced: about SEK 430M · DNB Carnegie Investment Bank AB (publ)

    Dealers: DNB Carnegie Investment Bank AB (publ) (lead)

    Buyers: Redmile (Subscription commitment; together with other existing shareholders approximately SEK 80 million); Van Herk (Subscription commitment; together with other existing shareholders approximately SEK 80 million); Forbion (Subscription commitment; together with other existing shareholders approximately SEK 80 million); HealthInvest (Subscription commitment; together with other existing shareholders approximately SEK 80 million); DNB Bank ASA (Guarantee undertakings, with others, up to approximately SEK 270 million); Schonfeld Global Master Fund L.P. (Guarantee undertakings, with others, up to approximately SEK 270 million); Anavio Capital Partners LLP (Guarantee undertakings, with others, up to approximately SEK 270 million)

    Insiders: Shareholding board members and management intend to subscribe approximately SEK 0.6 million in total, including pro rata from CEO Martin Welschof and Chairman Leonard Kruimer

    Use of proceeds: Strengthen financial position and fund clinical development of priority programs, principally BI-1808 and BI-1206 in solid tumors

    Announced Oct 28, 2026

Read by 6ix AI from the company's releases

Decks

BioInvent International AB on 6ix

Sector
Health care
Industry
Biotechnology
News releases
14 in the last 12 months · 30 in all · newest Oct 28, 2026 · oldest 2025
Calls
2 calls with a replay · 2 with a transcript · latest Feb 26, 2026
Decks
23 decks · latest October 2026

Where BioInvent International AB is listed

ListingExchangeCountryCurrency
Stockholm:BINV · Home listingStockholmSwedenSEK
Aquis:BINVSAquisUnited KingdomSEK
Stuttgart:BIX0StuttgartGermanyEUR
LS Exchange:A2QJRWLS ExchangeGermanyEUR
Lang & Schwarz:A2QJRWLang & SchwarzGermanyEUR
gettex:BIX0gettexGermanyEUR
Frankfurt:BIX0FrankfurtGermanyEUR
Dusseldorf:BIX0DusseldorfGermanyEUR
LSIN:0H22LSINUnited KingdomSEK
Munich:BIX0MunichGermanyEUR
OTC:BOVNF · This pageOTCUnited StatesUSD
Aquis:BINVSAquisUnited KingdomSEK
Turquoise:BINVSTurquoiseUnited KingdomSEK

Log in to ask 6ix AI your own questions about BioInvent International AB.